1	COVID-19 Surveillance in the Biobank at the Colorado Center for Personalized Medicine
2	Randi K. Johnson <sup>1,2,3</sup> +, Katie M. Marker <sup>1,2,4</sup> +, David Mayer <sup>1</sup> , Jonathan Shortt <sup>1</sup> , David Kao <sup>1,2</sup> ,
3	Kathleen C. Barnes <sup>1,2</sup> , Jan T. Lowery <sup>2,3</sup> +, Christopher R. Gignoux <sup>1,2,4</sup> +
4	1. Division of Biomedical Informatics and Personalized Medicine, Department of Medicine,
5	University of Colorado School of Medicine
6	2. Colorado Center for Personalized Medicine, University of Colorado
7	3. Department of Epidemiology, Colorado School of Public Health
8	4. Human Medical Genetics and Genomics Program, University of Colorado Anschutz
9	Medical Campus
10	
11	+ contributed equally
12	
13	ABSTRACT
14	Background: Characterizing the experience and impact of the COVID-19 pandemic among
15	various populations remains challenging due to the limitations inherent in common data sources
16	such as the electronic health record (EHR) or convenience sample surveys.
17	Objective: To describe testing behaviors, symptoms, impact, vaccination status and case
18	ascertainment during the COVID-19 pandemic using integrated data sources.
19	Methods: In summer 2020 and 2021, we surveyed participants enrolled in the Biobank at the
20	Colorado Center for Personalized Medicine (CCPM, N = 180,599) about their experience with
21	COVID-19. Prevalence of testing, symptoms, and the impacts of COVID-19 on employment,
22	family life, and physical and mental health were calculated overall and by demographic

23 categories. Using the Electronic Health Record (EHR), we compared COVID-19 case

ascertainment and characteristics in the EHR versus the survey.

25 **Results:** Of the 25,063 survey respondents (13.9%), 42.5% had been tested for COVID-19 and of those, 12.8% tested positive. Nearly half of those tested had symptoms and/or had been 26 27 exposed to someone who was infected. Young adults (18-29 years) and Hispanics were more 28 likely to have positive tests compared to older adults and persons of other racial/ethnic groups. 29 Mental health (54.6%) and family life (48.8%) were most negatively affected by the pandemic 30 and more so among younger groups and women; negative impacts on employment were more 31 commonly reported among Black respondents. After integration with EHR data up to the time of the survey completion, 4.0% of survey respondents (n=1,006) had discordant COVID-19 case 32 33 status between the EHR and the survey. Using all longitudinal EHR and survey data, we 34 identified 11,472 COVID-positive cases among Biobank participants (6.4%). In comparison to 35 COVID-19 cases identified through the survey, EHR-identified cases were younger and more 36 likely to be Hispanic. 37 Conclusions: Integrated data assets such as the Biobank at the CCPM are key resources for 38 population health monitoring in response to public health emergencies, such as the COVID-19 39 pandemic. 40 41 **Trial Registration:** N/A. 42

43 **Keywords:** COVID-19, surveillance, pandemic, biobank, EHR

44

45 INTRODUCTION

46	The Coronavirus Disease 2019 (COVID-19) global pandemic has caused significant
47	burden on the health and well-being of our families and communities. It has changed the way we
48	work, socialize, and go about our daily lives. To date, over 888,000 Americans have died from
49	COVID-19 and more than 49 million have been infected with the virus, many of whom have
50	been hospitalized and/or suffered from a range of symptoms lasting from days to years [1].
51	Further, the burden of this disease, with respect to infection rates, hospitalizations, deaths and
52	impacts on physical and mental health is not evenly distributed throughout the population.
53	Understanding the nature and magnitude of this disease has been challenging due to the evolving
54	nature of this virus, changing recommendations from public health around testing and self-
55	quarantine, and our own health behaviors to avoid exposure.
56	As we strive to understand this novel virus in terms of risk and outcomes, it is important
57	to assess the impact of COVID-19 among various populations including those who may
58	experience serious versus mild effects from infection, those who experience symptoms but do
59	not undergo testing, and those who never contract the disease. This broad inquiry requires
60	multiple data sources. Electronic health records (EHR) are useful for capturing information on
61	persons who seek medical care and/or become hospitalized due to COVID-19, and thus may
62	reflect more severe cases [2-4]. However due to incomplete and unstructured data collection in
63	EHRs, self-reported population surveys can provide information on persons with more mild
64	disease who may opt not to seek medical care and those never infected [5]. Combining data
65	sources from the EHR and surveys can mitigate limitations and biases inherent in each as well as
66	optimize capture of the COVID-19 experience in a broader population.
67	We sought to characterize the experience and impact of the COVID-19 virus among a

68 large and diverse group of persons enrolled in the Biobank at the Colorado Center for

Personalized Medicine (CCPM), a collaborative initiative supported by UCHealth and the University of Colorado Anschutz Medical Campus. Specifically, we assessed the prevalence of testing and positive test results, the type and frequency of symptoms, health-care utilization, severity of disease, and the impacts of the pandemic on mental and physical health and employment. Uniquely, for this analysis, we were able to combine clinical data from the EHR, with self-reported information collected via an online survey that was offered to all Biobank participants.

We present here results from our analysis of self-reported survey data and clinical data
recorded in the EHR for Biobank participants. By combining these unique data sources, we were
able to capture more COVID-19+ cases and assess population differences in symptoms,
healthcare utilization, severity (hospitalization), and personal impact. We also highlight the value
of biobanks such as ours in facilitating rapid and comprehensive inquiries about emerging public
health threats like COVID-19.

82

### 83 METHODS

### 84 Study Population

Enrollment in the CCPM Biobank is open to all UCHealth patients who are 18 years of age or older and able to provide consent for themselves through My Health Connection, the mobile EHR patient portal for UCHealth. Enrolled participants consent to use of their clinical data from the EHR and to being re-contacted about new research opportunities and to complete surveys. To date, the Biobank has enrolled over 200,000 adult participants from among the 2.5 million UCHealth patients across Colorado. Biobank participants are representative of the whole UCHealth population with respect to age, gender, race/ethnicity and co-morbidity status 92 (Multimedia Appendix 1). For this study, all living Biobank participants with a valid email
93 address were invited to complete an online survey about their experience with the COVID-19
94 pandemic. We linked survey responses with participants' demographic and clinical data from the
95 EHR that are captured and stored within Health Data Compass (Compass), the clinical data
96 warehouse for UCHealth and the CCPM Biobank.

### 97 Survey Development and Administration

98 We developed our survey based on an instrument developed by the International 99 Common Disease Alliance (ICDA) [6] early in the pandemic. Our survey included questions 100 about testing for COVID-19, test results, symptoms related to COVID-19 infection, health care 101 utilization following a positive test and/or symptoms, underlying health conditions, the impact of 102 COVID-19 on health and well-being, potential household exposure to COVID-19, and current 103 smoking behaviors (Multimedia Appendix 2). We created the survey in REDCap [7], a HIPAA-104 compliant database and research management platform, and created unique survey links for each 105 Biobank participant. Personal invitations to complete the survey were sent by email to all 106 participants beginning in June 2020 with a follow-up reminder to non-responders within 2 107 weeks. We repeated the process in October 2020 to all newly enrolled participants between June 108 and October 2020. We revised the survey in March 2021 to include additional questions on 109 vaccine uptake, adverse reactions to the vaccine and long-term symptoms post infection 110 (Multimedia Appendix 3). The revised survey was sent to all participants who hadn't responded 111 to the initial survey and newly enrolled participants through May 2021. In total, survey invites 112 were sent to 180,599 individual participants over the course of 15 months.

113 COVID-19 Case and Severity Definitions: Survey and EHR

Survey respondents who reported receiving a positive COVID-19 test result were considered a "confirmed case" of COVID-19. Self-reported cases also reported whether the respondent tested positive for COVID-19, saw a doctor in-person or through telehealth, visited the emergency room, were hospitalized overnight, stayed home/isolated, or did nothing different. We looked at severity either in terms of hospitalization due to COVID-19 or death after COVID-19. Respondents who reported having one or more overnight stays in the hospital were considered to be 'hospitalized'.

121 Positive cases were identified in the EHR using ICD-10 diagnosis codes, healthcare 122 encounter types, and encounter primary diagnoses. Participants who received an ICD-10 123 diagnosis code of U07.1 or at least one of 11 COVID-19 specific encounter primary diagnoses 124 (Multimedia Appendix 4) were considered an "EHR-confirmed case". Participants who were 125 hospitalized in a UCHealth hospital overnight during the 3 days before or up to 21 days after 126 their COVID-19 diagnosis date and who had at least one of 64 COVID-19 related encounter 127 primary diagnoses (Multimedia Appendix 5) were considered to be "EHR-hospitalized." To 128 compare positive cases identified from the EHR and survey, we examined the number of 129 hospitalized cases that were discordant between these data sources.

All-cause mortality data stored in the Health Data Compass clinical data warehouse
include the cause of death as certified by a physician or coroner/medical examiner, related ICD10 cause of death codes generated by Centers for Disease Control, and age at death. These data
are obtained through routine linkage of UCHealth patients with the vital statistics/death
certificates provided by the Department of Vital Statistics at the Colorado Department of Public
Health and the Environment (CDPHE). Accounting for the ~3-month lag time to register

136 certificates, map ICD-10 cause of death codes, and update the clinical databases, the

137 ascertainment of mortality among UCHealth patients for this analysis is nearly 95% complete.

### **138 Other Definitions**

Age and race-ethnicity were determined from the EHR.. Race and ethnic indicators were extracted as encoded in the EHR and categorized into 4 racial-ethnic groups to preserve >10 individuals in each group in all analyses, including: non-Hispanic White, non-Hispanic Black, any Hispanic, other.

### 143 Statistical Analysis

144 We generated descriptive statistics to characterize our study population and responses to 145 survey questions. We also stratified respondents with respect to COVID-19 infection status 146 based on reported test status and symptomology. We compared COVID-19+ individuals that 147 were identified via the survey and via the EHR by demographics and severity (overnight 148 hospitalization and death). We investigated case status and hospitalization misclassification in 149 both the survey and EHR by comparing those who were discordant in the survey and EHR. We 150 calculated differences between groups using chi-square and t-test statistics for categorical and 151 continuous measures, respectively. As expected, due to very large sample size in the study, most 152 comparisons were statistically significant at a two-sided alpha < 0.05. Therefore, we focus results 153 and interpretation on effect sizes and corresponding standard error of the estimate.

154

### 155 **RESULTS**

156 Survey response

Of 180,599 biobank participants with valid email addresses, 25,063 completed at least
one survey and had complete demographic information (response rate = 13.9%, Figure 1).

- 159 Compared to non-respondents (Multimedia Appendix 6), respondents were older (mean age =
- 160 55.0 years vs. 48.6 years, P < .001) and enriched for a higher proportion of females (62.6% vs.
- 161 59.0%, *P*<.001) and individuals of non-Hispanic White race-ethnicity (87.4% vs. 77.1%,
- 162 *P*<.001).
- 163



### 165 Figure 1: The Biobank at the Colorado Center for Personalized Medicine COVID-19

- 166 Survey Population.
- 167

### 168 COVID-19 Testing

```
Among all survey respondents, 42.5% (n=10,661) reported being tested for COVID-19.
```

- 170 The most common reasons for testing were having symptoms (29.5%), exposure to someone
- 171 who tested positive for COVID-19 (18.5%), doctor recommendation (14.7%), requirement of
- 172 employer (8.9%), and recent international travel (3.4%). An additional 40.8% of individuals

tested, reported 'other' reasons for testing that included having surgery or other medical
procedure, planned travel, desire or need to be around large groups or family members and worksite offerings for testing.

176 Of those tested, 1366 (12.8%) tested positive for COVID-19 (Table 1) and were 177 considered confirmed cases. The distributions of age, sex, race-ethnicity, college education, 178 number of symptoms, number of pre-existing comorbidities, overall health status, and exposure 179 to a household member who tested positive for COVID-19 were different across the three groups 180 of those who tested positive, tested negative, and were not tested (all P<.001). Young adults 181 (ages 18-29 years) were overrepresented among the tested-positive group, representing 10.7% of 182 those who tested positive compared to 6.7% of those who tested negative and 5.1% of those who 183 were not tested (*P* for trend <.001). Similarly, individuals of Hispanic race-ethnicity were 184 overrepresented in the tested-positive group at 9.2%, compared to 5.7% of those who tested 185 negative and 4.3% of those who were not tested. Individuals who tested positive were also more 186 likely to report symptoms, household exposure to COVID-19 and poor health status (Table 1, all 187 *P*<.001).

	Total	Tested			Not Tested		
		Tested Positive	Tested Negative	<i>P</i> -	N=14,402	<i>P</i> -	P- value***
Characteristics	N=25,063	N=1366	N=9295	value*		value**	
	55.0	48.9					
Age, mean (SD)	(15.8)	(14.6)	53.7 (15.6)	<.001	56.5 (15.8)	<.001	<.001
Age, n (%)				<.001		<.001	<.001
	1503	146	619				
18-29	(6.0%)	(10.7%)	(6.7%)		738 (5.1%)		
	15049	1000	5890		8159		
30-64	(60.0%)	(73.2%)	(63.4%)		(56.7%)		
	8511	220	2786		5505		
65+	(34.0%)	(16.1%)	(30.0%)		(38.2%)		
Sex, n (%)				0.09		<.001	<.001
	15695	902	5915		8878		
Female	(62.6%)	(66.0%)	(63.6%)		(61.6%)		
	9368	464	3380		5524		
Male	(37.4%)	(34.0%)	(36.4%)		(38.4%)		
Race-Ethnicity, n (%)				<.001		<.001	<.001
L	21916	1117	8072		12727		
Non-Hispanic White	(87.4%)	(81.8%)	(86.8%)		(88.4%)		
N H' DI 1	308	24.0	133		151 (1.00()		
Non-Hispanic Black	(1.2%)	(1.8%)	(1.4%)		151 (1.0%)		
<b>TT</b>	1272	125	528		(10 (1.20))		
Hispanic	(5.1%)	(9.2%)	(5./%)		619 (4.3%)		
Other	1567	100	562		0.05(6.20/)		
Other (a)	(6.3%)	(7.3%)	(6.0%)	0.01	905 (6.3%)	0.10	0.0.1
Bachelors Degree, n (%)				<.001		0.13	<.001
¥7	19407	973	7219		11215		
Yes	(//.4%)	(/1.2%)	(//./%)		(77.9%)		
N.	5482	381	2008		3093		
No	(21.9%)	(27.9%)	(21.6%)		(21.5%)		
Unknown	174	12.0	68.0		94.0		
Number of Ac40	0.770)	2.00	0.202		0.00000		
Symptoms mean (SD)	(1.05)	2.09	0.393	< 001	(0.00222)	< 001	< 001
Number of Comercidities	1.51	1.46	(1.13)	<u>\.001</u>	(0.0077)	~.001	<u>\.001</u>
mean (SD)	(1.31)	(1.46)	1.59 (1.44)	0.004	1.46 (1.32)	<.001	<.001
Health Status n (%)	(1.50)	(1.10)		< 001	1.10 (1.52)	< 001	< 001
incultin Sturius, II (70)	5664	235	1003	<.001	3/36	<.001	×.001
Excellent	(22.6%)	(17.2%)	(21.4%)		(23.9%)		

# 189 Table 1: COVID-19 Testing in the Biobank among Survey Respondents

Very Good	10532 (42.0%)	444	3784 (40,7%)		6304 (43.8%)			
	6558	440	2527		3591			
Good	(26.2%)	(32.2%)	(27.2%)		(24.9%)			
	1859	196	793					
Fair	(7.4%)	(14.3%)	(8.5%)		870 (6.0%)			
Deer	323	45.0	151		127 (0.00()			
	(1.5%)	(5.5%)	(1.0%)		74.0			
Unknown	(0.5%)	6.00 (0.4%)	47.0 (0.5%)		(0.5%)			
Questionnaire Version, n								
(%)				<.001		<.001	<.001	
	14814	410	3718		10686			
1-Summer-Fall 2020	(59.1%)	(30.0%)	(40.0%)		(74.2%)			
2 Summer Fell 2021	10249	956 (70.0%)	5577		3716			
	(40.9%)	(70.0%)	(00.0%)		(23.8%)			
(%)				<.001		<.001	<.001	
	717	519	125		73.0			
Yes	(2.9%)	(38.0%)	(1.3%)		(0.5%)			
	24346	847	9170		14329			
No	(97.1%)	(62.0%)	(98.7%)		(99.5%)			
Household Member Tested Positive, n (%)				<.001		<.001	<.001	
	19472	482	7268		11722			
No	(77.7%)	(35.3%)	(78.2%)		(81.4%)			
Yes	1519 (6.1%)	691 (50.6%)	517 (5.6%)		311 (2.2%)			
	4072	193	1510		2369			
Unknown	(16.2%)	(14.1%)	(16.2%)		(16.4%)			
Genetic Data, n (%)				0.17		<.001	<.001	
	20182	1157	7732		11293			
No	(80.5%)	(84.7%)	(83.2%)		(78.4%)			
37	4881	209	1563		3109			
Yes	(19.5%)	(15.3%)	(16.8%)		(21.6%)			
* From chi-square or anova, c	* From chi-square or anova, comparing tested positive vs. tested negative							
** From chi-square or anova, comparing tested vs. not tested								
*** From chi-square or anova, comparing tested positive vs. tested negative vs. not tested								

192 COVID-19 Case Symptomology

193	Out of the 1,366 COVID-19+ individuals identified from the survey, 1,154 (84.4%)
194	individuals had at least one of the following COVID-19 related symptoms since February 2020:
195	cough, fever over 99.9°F, general tiredness/fatigue, muscle/body aches, runny nose, difficulty
196	breathing/shortness of breath, loss of sense of smell or taste, stomach or gastrointestinal (GI)
197	problems (Figure 2). However, only 48.4% reported at least one symptom 14 days before or
198	after a positive COVID-19 test ( $n = 661$ ). The number of symptoms individuals reported is
199	relatively even from one to eight symptoms, ranging from $3.7\%$ (n = 50) reporting all eight
200	symptoms and 8.4% ( $n = 115$ ) reporting four symptoms (Figure 2A). General tiredness/fatigue
201	and muscle/body aches were the most commonly reported symptoms within 14 days of a positive
202	COVID-19 test, at 37.8% and 31.2%, respectively (Figure 2B). Next most common was loss of
203	sense of smell or taste, with 397 (29.1%) reporting within 14 days of a positive COVID-19 test
204	(Figure 2B). However, an additional 283 individuals reported this symptom outside the 28-day
205	window. A quarter of individuals reported a cough within 14 days of a positive COVID-19 test
206	(n = 346) and 22.7% and 22.1% reported difficulty breathing/shortness of breath and a runny
207	nose, respectively (Figure 2B). Only 17.1% of individuals ( $n = 234$ ) reported stomach or GI
208	problems (Figure 2B). The remainder (51.6%) reported no symptoms within 14 days before or
209	after their COVID-19 positive test ( $n = 705$ ). There were no significant differences in
210	asymptomatic cases compared to symptomatic cases (having at least one symptom) when
211	comparing by age, sex, or race/ethnicity (Figure 2C-E).





distributions across demographic groups. Error bars indicate the 95% confidence interval for thepercent point estimate.

221

### 222 Health Behaviors and Impact on Healthcare System

223 To assess health behaviors among COVID-19 cases and the potential impact on the 224 healthcare system, we asked these individuals what they did as a result of testing positive (Figure 225 3A). Eighty-one percent of the 1,366 respondents with positive tests stayed home and self-226 isolated (n = 1108), and 5.6% did not report any changes in behavior (n = 76) (Figure 3A). Of 227 those who did not change behavior, 82.9% did not have any symptoms reported 14 days before 228 or after their COVID-19 test (n = 63). Among the 1,366 positives, 625 (45.8%) of those sought 229 out at least one form of medical care. One hundred ninety (14%) saw a doctor at an in-person 230 visit, 454 (33.2%) saw a doctor via telehealth, 14.2% went to the emergency room (n = 194) and 231 7.9% had an overnight stay in a hospital (n = 108) (Figure 3A). A subset of 229 (16.7%) 232 individuals reported being tested at a UCHealth facility (n = 229, 16.7%) vs. 213 (15.6%) outside 233 UCHealth with no response from 924 respondents. Of the 229 respondents who said they tested 234 positive at a UCHealth facility, only 59.8% (n = 137), were identified as a 'case' within the 235 EHR. There is a high rate of missingness for the question on who performed the test (67.6%), so 236 there may be confusion by participants about who supplied the COVID-19 test. 237 Among respondents who were not tested but reported having at least 1 COVID-related

symptom, 1901 (41.9%) said they did nothing different, whereas 1920 (42.3%) stayed home and

self-isolated (Figure 3B). A third (n = 1,515) sought out at least one form of medical care, 934

240 (20.6%) had an in-person clinic visit, 77 (17.1%) had a telehealth clinic visit, 275 (6.1%) went to

the ER, and 90 (2.0%) had an overnight stay in the hospital (Figure 3B).









- 248 confidence interval for the percent point estimate.



251	The impact of the COVID-19 pandemic on employment, family life, mental health or
252	physical health was largely negative, with more than 75% of respondents (n=18,861) reporting a
253	negative impact from the COVID-19 pandemic in at least one of these domains, compared to
254	23% of respondents (n=5,856) reporting a positive impact in at least one domain ( $P$ <.001).
255	Mental health and family life were most negatively affected by the pandemic, at 54.6%
256	(n=13,688) and 48.8% (n=12,233) of respondents reporting a negative impact, respectively.
257	Negative impact in other two domains was lower at 28.2% (n=7,059) for physical health and
258	21.2% (n=5,320) for employment ( <i>P</i> <.001).
259	The impact of the COVID-19 pandemic was not equal across groups by age, race-
260	ethnicity, sex, and COVID-19 testing status (max P=.006, Figure 4). A higher proportion of
261	young adults reported a negative mental health impact (74.9%, $95\%$ CI = 72.7-77.1%) than adults
262	aged 30-64 years (60.7%, 95% CI = 59.6-61.5%) and older adults, 65+ years (41.1%, 95% CI = $(41.1\%)$
263	40.1-42.2%). A similar linear trend across age groups was seen for the negative impact of the
264	pandemic on employment and physical health (Figure 4A). Using self-reported race-ethnicity as
265	captured in the EHR, a higher proportion of non-Hispanic Black respondents reported a negative
266	impact on their employment (35.8%, $95\%$ CI = 30.4-41.2%) compared to other race-ethnic
267	groups (all proportions < 26.1%, Figure 2B). Women reported greater negative impact in all four
268	domains compared to men, at (respectively) 23.4% versus 18.3% in employment, 50.5% versus
269	47.0% in family life, 60.3% versus 46.0% in mental health, and 30.7% versus 24.4% in physical
270	health (Figure 4C, all P<.001). Respondents who tested positive for COVID-19 reported a higher
271	negative impact on their physical health (55.0%, $95\%$ CI = 52.3-57.6%) than those who tested
272	negative (30.9%, $95\%$ CI = 30.0-31.9%) and those who did not report a COVID-19 test (24.2%,
273	95%CI = 23.5-24.9%, Figure 4D).



276 Figure 4: The impact of COVID-19 on employment, family life, mental and physical health

by A) age, B) race-ethnicity, C) sex, and D) COVID-19 test status. P = p-value from

278 Pearson's chi-square test for different distributions across impact and demographic groups. Error

bars indicate the 95% confidence interval for the percent point estimate.

280

### 281 COVID-19 Vaccination

In our second round of the survey (administered Spring/Summer 2021), we added

questions about COVID-19 vaccination. Of the 10,249 individuals who responded, 95.3% had

- received the vaccine (n = 9,770). Younger people were less likely to have received a vaccine:
- 285 7.5% of those aged 18-29 years did *not* receive a vaccine compared to 4.9% of individuals ages
- 286 30-64 years and 2.0% of individuals 65 + (P < .001, Figure 5A). Women were slightly less likely









305

## 306 Figure 6: COVID-19 positive CCPM Biobank participants identified through the

## 307 UCHealth EHR and the Survey.

308

309 In comparing COVID-19 cases from the EHR to those in the survey (**Figure 7**), we found

that cases identified in the EHR were younger, with 17.2% of individuals in the 18-29 age group

311 compared to 10.7% in the survey group (*P*<.001, Figure 7A). A higher percentage of cases

identified in the EHR were Hispanic compared to survey cases (14.7% vs 9.2%, respectively, P<.001, Figure 7B). The EHR cases also had a slightly lower proportion of women (61.9%) compared to the survey group (66.0%); (P = 0.003, Figure 7C). The median income for the 3digit zip code was the same, \$69,900 in both groups. The median percent of the population who received a bachelor's degree by 3-digit zip code was slightly lower in the EHR group (41.3%) compared to the survey (45.7%), P<.001.





320 Figure 7: Comparison of COVID-19 cases captured in the EHR and the survey by A) age,

**B)** race/ethnicity, C) sex, and D) COVID-19 related overnight hospitalization. P = *p*-value

322 from Pearson's chi-square test for different distributions across impact and demographic groups.

323 Error bars indicate the 95% confidence interval for the percent point estimate.

324

### 325 Comparison of COVID-19 Case Severity in EHR versus Survey

A higher percent of COVID-positive cases identified from the survey were hospitalized overnight (8.3%) compared to the EHR group (6.5%) (P = 0.01, Figure 7D). Using all-cause mortality data obtained from CDPHE vital statistics, 130 (2.3%) individuals in the EHR case group died, leading to a death rate of 1.2%. Four people in the survey case group died, with a death rate of 0.22%.

331 The EHR is a longitudinal data source, therefore we can capture COVID-19 cases on a 332 continuing basis, whereas the survey reflects a point in time and can only identify individuals 333 who had COVID-19 before they took the survey. Among 907 COVID-19 cases identified in the 334 EHR who completed the survey but did not report a positive COVID-19 diagnosis in the survey, 335 41.8% reported receiving a negative COVID-19 test result (n = 379), and 58.2% had not taken a 336 COVID-19 test and were presumed to be negative (n = 528). The majority of these individuals 337 (80.7%) completed the survey before they were diagnosed with COVID-19 in the EHR (n = 338 732).

339

### 340 COVID-19 Case and Hospitalization Discordance between the EHR and Survey

341 To quantify discordance of COVID-19 case status between the EHR and the survey we
342 looked across our entire set of survey respondents (n = 25,063). We only counted a participant as

343 "EHR COVID-19+" if the diagnosis was prior to taking the survey, not COVID-19 cases that 344 happened after the survey was taken. While neither the survey nor the EHR are a gold standard 345 for case classification, we can look at the discordance between them to identify the potential for 346 misclassification. Overall, there were a total of 1,006 respondents discordant for COVID-19 347 case-status (4%). One hundred seventy-three individuals of the 25,063 individuals who took the 348 survey were identified as COVID-19+ in the EHR but negative or not tested in the survey, 349 leading to a discordance rate of 0.7% (Table 2). 833 individuals were identified as COVID-19+ 350 in the survey but negative in the EHR, leading to a discordance rate of 3.3%.

351

352 Table 2: Case Status Misclassification Between the Survey and EHR

		Survey COVID Other	
	Survey COVID+	(Negative or Not Tested)	Total
EHR COVID+	533	173	706
EHR COVID Other (Negative or Not Tested)	833	23524	24357
Total	1366	23697	25063

353

To quantify discordance of hospitalization status in both the EHR and in the survey, we restricted it to individuals who responded to the survey and were either COVID-19 positive in the EHR or the survey (n = 2,273). EHR hospitalizations were only considered if they were prior to taking the survey. There were 6 individuals who were positive for hospitalization in the EHR but negative in the survey, a discordance rate of 0.3% (**Table 3**). There were 59 individuals who were positive for hospitalization in the survey who were negative in the EHR, a discordance rate of 2.6%.

362

	Survey Hospitalization +	Survey Hospitalization -	Total
EHR Hospitalization +	49	6	55
EHR Hospitalization -	59	2159	2218
Total	108	2165	2273

#### 364 Table 3: Hospitalization Misclassification Between the Survey and EHR

#### 365

### 366 **DISCUSSION**

367 We found that the COVID-19 pandemic has had far-reaching and varying effects among 368 our Biobank participants. Over 84% of the 25,063 survey respondents reported having one or 369 more COVID-related symptoms since February 2020, 40% were tested for the virus, 13% of 370 those tested were positive, and among positive cases, 45% sought medical care following their 371 diagnosis. Our overall case positivity rate of 13% is comparable to those reported by other EHR-372 based retrospective studies conducted in 2020 and 2021 [8, 9]. However, our finding of higher 373 positivity rates among our younger participants (aged 18-39 years; 20%) and Hispanics (19%) in 374 our participants has not been reported previously and may reflect differences in reasons for 375 testing in these groups (e.g. due to having symptoms or recent exposure vs. other reasons). 376 Though not surprising that a large proportion of respondents reported having symptoms given 377 the breadth of symptoms reported (e.g. runny nose, fever, body aches), it is notable that 40% of 378 those with symptoms did not undergo testing nor seek medical care. It is likely that a percentage 379 of this group had COVID-19 and would not be counted as such via public health surveillance 380 efforts, which could lead to substantial underestimates of the true infection rate in the general 381 population.

The vast majority of all survey respondents (75%) reported a negative impact from the COVID-19 pandemic—most commonly around mental health and family life. We found that females more often reported negative impacts than males in all domains–employment, family

385 life, mental and physical health. This disproportionate negative impact on females is consistent 386 with prior public health emergencies [10], including the 2016 Zika and 2014 Ebola outbreaks 387 [11]. Among U.S. women, this has been described in several areas, including the healthcare 388 workforce, reproductive health, drug development, gender-based violence, and mental health 389 [12]. It is both notable and concerning that nearly 75% of younger adults (aged 18-29 years) 390 reported negative impacts on their mental health, which was higher than for any other group. The 391 younger end of this range captures members of Generation Z, who are more likely to report poor 392 mental health compared to prior generations [13, 14]. However, they are also more likely to 393 receive mental health therapy or treatment [13], and therefore may accept interventions to 394 address the negative mental health consequences of the COVID-19 pandemic. Further, we found 395 that negative impacts on employment were more commonly reported among Black participants. 396 These findings highlight the breadth of negative impacts of this pandemic in our community, and 397 reveal the disproportionate impact experienced by certain subgroups that should be targeted in 398 future intervention efforts.

399 Our study population had a much higher vaccination rate compared to Colorado overall 400 and the general US population. Over 95% of our survey participants are fully vaccinated 401 compared to 76% of adults throughout Colorado [15]. Vaccination directly reduces likelihood of 402 infection and severity of disease but it also has an indirect effect on society via reduced viral 403 transmission and herd immunity. Because of this impact on others, getting vaccinated is 404 considered a prosocial behavior [16-18]. Being a participant in a biobank has also been 405 positively associated with prosocial behavior, as the individuals who participate in biobanks tend 406 to be motivated by furthering research for the greater good [19, 20]. Since our study population 407 only includes those who elected to be in the biobank and additionally, those who responded to

the survey, these are likely individuals with high levels of prosocial behaviors, which likely
explains the high vaccination rate. Given our highly self-selected study population, results may
not generalize outside of the CCPM Biobank and UCHealth population. However, our ability to
incorporate EHR data allows us to build a research population of biobank participants that is
more representative of the entire patient population.

413 Differences between data captured in the EHR vs. those captured in the survey reveal the 414 benefit of using both sources in combination. For example, mild cases with sub-clinical 415 manifestations of infection that did not result in seeking care may be missing from the EHR but 416 captured in a survey. The EHR is a longitudinal data source that collects clinical information on all patients diagnosed with and/or treated for COVID-19 within the UCHealth system 417 418 irrespective of proclivity to participate in research or respond to surveys. As such, the EHR 419 captured data from Biobank participants that the survey did not. Periodic analysis of EHR data 420 will allow us to study COVID-19 reinfection and vaccine breakthrough cases over time. 421 However, UCHealth is not a closed system and Biobank participants can receive care outside of 422 UCHealth, so we recognize that not all individuals that were diagnosed or treated for COVID-19 423 are or will be captured in the EHR. We believe that the survey data more completely identifies 424 individuals who did not seek healthcare or sought care outside of the UCHealth system, in 425 particular patients who reported COVID-19 infection in the survey but had no corresponding 426 record in the EHR.

427 COVID-19 has variable clinical presentations ranging from asymptomatic infections to 428 severe symptoms that require hospitalization. We expected that COVID-19 patients identified in 429 the EHR would be sicker on average than survey only cases, more likely to have severe COVID-430 19 and less likely to have asymptomatic infections [22, 23]. However, we found that there was a 431 slightly higher percentage of COVID-19 hospitalizations among survey cases compared to EHR 432 cases. This unexpected result may be explained, in part, by the fact that the survey likely 433 undercounts deaths due to COVID-19, since the survey cannot identify anyone who died from 434 COVID-19 unless they took the survey in between being diagnosed with COVID-19 and dying, 435 whereas our clinical data warehouse (that combines EHR data with state vital statistics) will 436 capture all deaths reported to CDPHE. With respect to participant demographics, it notable that a 437 higher percentage of younger (18-29) and Hispanic/Latino positive cases were identified via the 438 EHR vs. the survey. This may in part be explained by lower survey response rates in these 439 groups. Hispanic/Latino individuals may have been less likely to take the survey because of language barriers (the survey was only in English), limited internet access or other structural 440 441 barriers[24]. Lower participation among Hispanic individuals is consistent with observations in 442 other outreach efforts [19806848] and is a limitation of the convenience survey design. 443 Additionally, the Hispanic population in Colorado, as in many other states, had higher incidence 444 of COVID-19 infections, hospitalizations, and death [4, 25-28], which may explain why they are 445 more likely to be identified through the EHR.

A key strength to this study is our ability to leverage an existing, living resource in the CCPM Biobank and survey engine to assess the health and wellbeing of our participants in ways that are not highlighted by the EHR. Further, because participants consent to re-contact, we have the opportunity to follow up with sub-populations within our cohort to collect additional information and monitor outcomes such as re-infection and vaccine uptake. Although our overall response to the survey was sizeable, we acknowledge that the composition of the underlying patient population at UCHealth who enrolled in the Biobank, and differential response to the survey may have introduced some bias and limited the generalizability of ourresults.

455

### 456 CONCLUSION

457 The combination of EHR and survey data provides a powerful opportunity to monitor and 458 study the on-going effects of the COVID-19 pandemic in our communities. As the pandemic 459 continues, there is a critical need for optimal COVID-19 case ascertainment in order to capture 460 both mild and severe cases, and to monitor specific long-term outcomes such as post-acute 461 sequelae of SARS-CoV-2 infection (PASC) or downstream breakthrough infections post-462 vaccination. In an open health system as is common in the United States, the development of a 463 combined resource such as ours (with EHR and survey data) represents long-term potential for 464 additional recruitment and follow-up as a critical complement to large-scale informatics-focused 465 investigations such as the National COVID Cohort Collaborative[29]. As the pandemic 466 continues, we anticipate that resources such as the CCPM Biobank and other biobanks will 467 continue to be a key resource for ongoing data collection relevant to population health 468 monitoring during the era of COVID-19 and other emerging public health issues. 469

### 470 ACKNOWLEDGMENTS

We would like to thank all participants in CCPM, as well as the entire CCPM team making these
research initiatives a possibility in the pandemic. CCPM is supported by UCHealth and the
University of Colorado Anschutz Medical Campus. We thank Eric Campbell for assistance on
survey design. The research derivation of the EHR was made possible by the Health Data
Compass Data Warehouse project (healthdatacompass.org). KMM and CRG are partially

- 476 supported by R01HG011345. The REDCap database in this publication was supported by
- 477 NIH/NCATS Colorado CTSA Grant Number UL1TR002535. The contents are the authors' sole
- 478 responsibility and do not necessarily represent official NIH views.
- 479
- 480 CONFLICTS OF INTEREST
- 481 All authors report no relevant conflicts of interest.
- 482

### 483 **REFERENCES**

484 1. CDC. COVID-19. Centers for Disease Control and Prevention; [cited 2021 12/10/2021];
485 Available from: <u>https://www.cdc.gov/coronavirus/2019-ncov/index.html</u>.

Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID19 Outcomes by Race, Ethnicity, and Socioeconomic Status: A Systematic-Review and Metaanalysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147. PMID: 34762110. doi:
10.1001/jamanetworkopen.2021.34147.PMC8586903

490 3. Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro NI, Files DC, Gibbs KW, et al.
491 Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical
492 Centers, United States, March-May 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul
493 3;69(26):841-6. PMID: 32614810. doi: 10.15585/mmwr.mm6926e3.PMC7332092

494
4. Acosta AM, Garg S, Pham H, Whitaker M, Anglin O, O'Halloran A, et al. Racial and
495
496 Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit
496 Admission, and In-Hospital Death in the United States From March 2020 to February 2021.

497 JAMA Netw Open. 2021 Oct 1;4(10):e2130479. PMID: 34673962. doi:

498 10.1001/jamanetworkopen.2021.30479.PMC8531997

Morlock R, Morlock A, Downen M, Shah SN. COVID-19 prevalence and predictors in
United States adults during peak stay-at-home orders. PLoS One. 2021;16(1):e0245586. PMID:
33481900. doi: 10.1371/journal.pone.0245586.PMC7822538

502 6. International Common Disease Alliance. [January 10, 2022]; Available from:
 503 <u>https://www.icda.bio/</u>.

504 7. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
505 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
506 translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. PMID:
507 18929686. doi: 10.1016/j.jbi.2008.08.010.PMC2700030

Lindsay L, Secrest MH, Rizzo S, Keebler DS, Yang F, Tsai L. Factors associated with
 COVID-19 viral and antibody test positivity and assessment of test concordance: a retrospective
 cohort study using electronic health records from the USA. BMJ Open. 2021 Oct
 Lil(10):e051707 DMD: 24508088. doi: 10.1126/hmienen.2021.051707 DMC8488284

511 1;11(10):e051707. PMID: 34598988. doi: 10.1136/bmjopen-2021-051707.PMC8488284

512 9. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who

513 Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study.

514 Clinical Infectious Diseases. 2021;73(10):1882-6. doi: 10.1093/cid/ciab234

515 10. Smith J. Overcoming the 'tyranny of the urgent': integrating gender into disease outbreak
516 preparedness and response. Gender & Development. 2019;27(2):355-69.

517 11. Davies SE, Bennett B. A gendered human rights analysis of Ebola and Zika: locating
518 gender in global health emergencies. International Affairs. 2016;92(5):1041-60.

- 519 12. Connor J, Madhavan S, Mokashi M, Amanuel H, Johnson NR, Pace LE, et al. Health
- 520 risks and outcomes that disproportionately affect women during the Covid-19 pandemic: A
- 521 review. Soc Sci Med. 2020 Dec;266:113364. PMID: 32950924. doi:
- 522 10.1016/j.socscimed.2020.113364.PMC7487147
- 523 13. Association AP. 2018 Stress in America: Generation Z. Stress in America<sup>TM</sup> Survey.
  524 Washington, DC: American Psychological Association (APA), 2018.
- 525 14. Association AP. Stress in America<sup>TM</sup>: One Year Later, A New Wave of Pandemic Health
  526 Concerns. Washington, DC: American Psychological Association (APA), 2021.
- 527 15. CDPHE. Colorado COVID-19 Vaccination Data. Colorado Department of Public Health
  528 and the Environment; [12/17/2021]; Available from: <u>https://covid19.colorado.gov/vaccine-data-</u>
  529 <u>dashboard</u>.
- 530 16. Böhm R, Betsch C, Korn L, Holtmann C. Exploring and Promoting Prosocial
- Vaccination: A Cross-Cultural Experiment on Vaccination of Health Care Personnel. Biomed
   Res Int. 2016;2016:6870984. PMID: 27725940. doi: 10.1155/2016/6870984.PMC5048021
- 533 17. Böhm R, Betsch C, Korn L. Selfish-rational non-vaccination: Experimental evidence
  534 from an interactive vaccination game. Journal of Economic Behavior & Organization. 2016
  535 2016/11/01/;131:183-95. doi: <u>https://doi.org/10.1016/j.jebo.2015.11.008</u>
- 536 18. Cucciniello M, Pin P, Imre B, Porumbescu GA, Melegaro A. Altruism and vaccination
  537 intentions: Evidence from behavioral experiments. Soc Sci Med. 2021 Jul 13:114195. PMID:
  538 34602309. doi: 10.1016/j.socscimed.2021.114195
- 539 19. Broekstra R, Aris-Meijer J, Maeckelberghe E, Stolk R, Otten S. Demographic and
  540 prosocial intrapersonal characteristics of biobank participants and refusers: the findings of a
  541 survey in the Netherlands. Eur J Hum Genet. 2021 Jan;29(1):11-9. PMID: 32737438. doi:
  542 10.1038/s41431-020-0701-1.PMC7852517
- 543 20. Streicher SA, Sanderson SC, Jabs EW, Diefenbach M, Smirnoff M, Peter I, et al. Reasons
  544 for participating and genetic information needs among racially and ethnically diverse biobank
  545 participants: a focus group study. J Community Genet. 2011 Sep;2(3):153-63. PMID: 22109822.
  546 doi: 10.1007/s12687-011-0052-2.PMC3186034
- 547 21. CDPHE, Colorado State Emergency Operations Center, Testing & Notifications.
  548 [January 10, 2022]; Available from: <u>https://covid19.colorado.gov/testing-notifications</u>.
- 549 22. Violán C, Foguet-Boreu Q, Hermosilla-Pérez E, Valderas JM, Bolíbar B, Fàbregas550 Escurriola M, et al. Comparison of the information provided by electronic health records data
  551 and a population health survey to estimate prevalence of selected health conditions and
  552 multimorbidity. BMC Public Health. 2013 Mar 21;13:251. PMID: 23517342. doi: 10.1186/1471553 2458-13-251.PMC3659017

- Mizrahi B, Shilo S, Rossman H, Kalkstein N, Marcus K, Barer Y, et al. Longitudinal
  symptom dynamics of COVID-19 infection. Nat Commun. 2020 Dec 4;11(1):6208. PMID:
  33277494. doi: 10.1038/s41467-020-20053-y.PMC7718370
- Jang M, Vorderstrasse A. Socioeconomic Status and Racial or Ethnic Differences in
  Participation: Web-Based Survey. JMIR Res Protoc. 2019 Apr 10;8(4):e11865. PMID:
  30969173. doi: 10.2196/11865.PMC6479282
- 560 25. Podewils LJ, Burket TL, Mettenbrink C, Steiner A, Seidel A, Scott K, et al.
  561 Disproportionate Incidence of COVID-19 Infection, Hospitalizations, and Deaths Among
  562 Persons Identifying as Hispanic or Latino Denver, Colorado March-October 2020. MMWR
  563 Morb Mortal Wkly Rep. 2020 Dec 4;69(48):1812-6. PMID: 33270613. doi:
- 564 10.15585/mmwr.mm6948a3.PMC7714035
- Moore JT, Ricaldi JN, Rose CE, Fuld J, Parise M, Kang GJ, et al. Disparities in Incidence
  of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots
  During June 5-18, 2020 22 States, February-June 2020. MMWR Morb Mortal Wkly Rep. 2020
  Aug 21;69(33):1122-6. PMID: 32817602. doi: 10.15585/mmwr.mm6933e1.PMC7439982
- 27. Romano SD, Blackstock AJ, Taylor EV, El Burai Felix S, Adjei S, Singleton CM, et al.
  Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region United
  States, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Apr 16;70(15):560-5.
  PMID: 33857068. doi: 10.15585/mmwr.mm7015e2.PMC8344991
- 573 28. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic
  574 Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic
  575 Review. Ann Intern Med. 2021 Mar;174(3):362-73. PMID: 33253040. doi: 10.7326/m20576 6306.PMC7772883
- 577 29. National COVID Cohort Collaborative (N3C). [January 10, 2022]; Available from:
   578 <u>https://ncats.nih.gov/n3c</u>.

# ABBREVIATIONS

- CCPM Colorado Center for Personalized Medicine
- EHR Electronic Health Record